RECURRENT NON SMALL CELL LUNG CANCER
Clinical trials for RECURRENT NON SMALL CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new RECURRENT NON SMALL CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for RECURRENT NON SMALL CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug duo targets lung cancer in the brain after other treatments fail
Disease control CompletedThis study tested whether two drugs, amivantamab and lazertinib, could help control advanced lung cancer that has an EGFR mutation and has spread to the brain or spinal fluid. It was for patients whose cancer had gotten worse or spread to the central nervous system despite previo…
Matched conditions: RECURRENT NON SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
First human test of new lung cancer drug combo completed
Disease control CompletedThis study tested the safety and side effects of a new drug, ONO-7475, when given alongside the standard drug osimertinib. It involved 78 adults with advanced or recurrent non-small cell lung cancer that has a specific genetic change (EGFR mutation). The main goal was to find a s…
Matched conditions: RECURRENT NON SMALL CELL LUNG CANCER
Phase: PHASE1 • Sponsor: Ono Pharmaceutical Co. Ltd • Aim: Disease control
Last updated Mar 19, 2026 14:56 UTC